

**APC mutation associated with familial colorectal cancer in Ashkenazi jews****Publication number:** DE69814622T**Publication date:** 2004-02-26**Inventor:** LAKEN STEVE (US); GRUBER STEPHEN (US); PETERSEN GLORIA (US); KINZLER KENNETH (US); VOGELSTEIN BERT (US)**Applicant:** UNIV JOHNS HOPKINS (US)**Classification:****- international:** C12Q1/68; G01N33/574; C12Q1/68; G01N33/574; (IPC1-7): C12Q1/68; G01N33/574**- european:** C12Q1/68M6B; G01N33/574; G01N33/574C6**Application number:** DE19986014622T 19980121**Priority number(s):** US19970791883 19970131; WO1998US00961 19980121**Also published as:**

WO9833940 (A1)

EP0981644 (A1)

US5879890 (A1)

EP0981644 (A0)

CA2278781 (A1)

[more >>](#)[Report a data error here](#)

Abstract not available for DE69814622T

Abstract of corresponding document: **US5879890**

During routine screening of a patient with a family history of colorectal cancer for truncating APC mutations, a novel missense mutation was identified. Upon further evaluation, it was found that 6% of Ashkenazi Jews carry this mutation, and that it was present in DIFFERENCE 20% of Ashkenazis with a family history of CRC. Probes, methods, and kits for identifying individuals affected with this missense mutation are provided.

---

Data supplied from the **esp@cenet** database - Worldwide

**Characterising and identifying disseminated metastatic cancer cells****Publication number:** DE19736691**Publication date:** 1999-02-25**Inventor:** GIESING MICHAEL PROF DR MED (DE)**Applicant:** GIESING MICHAEL PROF DR MED (DE)**Classification:****- international:** C12Q1/68; C12Q1/68; (IPC1-7): C12Q1/68; G01N33/68**- european:** C12Q1/68M6B**Application number:** DE19971036691 19970822**Priority number(s):** DE19971036691 19970822**Also published as:**

WO9910528 (A1)

EP1007740 (A1)

US7056660 (B1)

EP1007740 (A0)

CA2301962 (A1)

[Report a data error here](#)**Abstract of DE19736691**

Characterising and identifying disseminated and metastatic cancer cells using RNA and DNA comprises examining a body fluid sample for at least one cancer-specific gene (I) and at least one cancer-associated gene (II). An Independent claim is also included for agents used in the new process, preferably in test and/or diagnostic kits.

---

Data supplied from the *esp@cenet* database - Worldwide